<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5112-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIFLUCAN 50 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUCONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Fareva Amboise" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Fareva Amboise
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER HOLDING FRANCE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Diflucan is one of a group of medicines called &ldquo;antifungals&rdquo;. The active substance is fluconazole.</p><p>&nbsp;</p><p>Diflucan is used &nbsp;to treat infections caused by fungi and may also be used to stop you from getting a candidal infection. The most common cause of fungal infections is a yeast called <em>Candida</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Adults</strong></p><p>You might be given this medicine by your doctor to treat the following types of fungal infections:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cryptococcal meningitis &ndash; a fungal infection in the brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coccidioidomycosis &ndash; a disease of the bronchopulmonary system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections caused by<em> Candida</em> and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mucosal thrush &ndash; infection affecting the lining of the mouth, throat and denture sore mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital thrush &ndash; infection of the vagina or penis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin infections &ndash; e.g. athlete&#39;s foot, ringworm, jock itch, nail infection</p><p>&nbsp;</p><p>You might also be given Diflucan to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stop cryptococcal meningitis from coming back</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stop mucosal thrush from coming back&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduce recurrence of vaginal thrush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stop you from getting an infection caused by <em>Candida</em> (if your immune system is weak and not working properly)</p><p>&nbsp;</p><p><strong>Children and adolescents (0 to 17&nbsp;years old)</strong></p><p>You might be given this medicine by your doctor to treat the following types of fungal infections:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mucosal thrush &ndash; infection affecting the lining of the mouth, throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections caused by <em>Candida</em> and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cryptococcal meningitis &ndash; a fungal infection in the brain</p><p>&nbsp;</p><p>You might also be given Diflucan to:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stop you from getting an infection caused by <em>Candida</em> (if your immune system is weak and not &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; working properly).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stop cryptococcal meningitis from coming back</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Diflucan </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to fluconazole, to other medicines you have taken to treat fungal infections or to any of the other ingredients of this medicine (listed in section 6). The symptoms may include itching, reddening of the skin or difficulty in breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking astemizole, terfenadine (antihistamine medicines for allergies)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking cisapride (used for stomach upsets)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking pimozide (used for treating mental illness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking quinidine (used for treating heart arrhythmia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking erythromycin (an antibiotic for treating infections)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Diflucan</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver or kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart disease, including heart rhythm problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have abnormal levels of potassium, calcium or magnesium in your blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you develop severe skin reactions (itching, reddening of the skin or difficulty in breathing)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you develop signs of &lsquo;adrenal insufficiency&rsquo; where the adrenal glands do not produce</p><p>adequate amounts of certain steroid hormones such as cortisol (chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking fluconazole</p><p>&nbsp;</p><p>Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with fluconazole treatment. Stop taking Diflucan and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist if the fungal infection does not improve, as alternative antifungal therapy may be needed.</p><p>&nbsp;</p><p><strong>Other medicines and Diflucan</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Tell your doctor <strong>immediately</strong> if you are taking astemizole, terfenadine (an antihistamine for treating allergies) or cisapride (used for stomach upsets) or pimozide (used for treating mental illness) or quinidine (used for treating heart arrhythmia) or erythromycin (an antibiotic for treating infections) as these should not be taken with Diflucan (see section: &ldquo;Do not take Diflucan if you&rdquo;).</p><p><strong>&nbsp;</strong></p><p>There are some medicines that may interact with Diflucan. Make sure your doctor knows if you are taking any of the following medicines as a dose adjustment or monitoring may be required to check that the medicines are still having the desired effect:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin or rifabutin (antibiotics for infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abrocitinib (used to treat atopic dermatitis, also known as atopic eczema)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alfentanil, fentanyl (used as anaesthetic)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amitriptyline, nortriptyline (used as anti-depressant)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amphotericin B, voriconazole (anti-fungal)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that thin the blood to prevent blood clots (warfarin or similar medicines)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; benzodiazepines (midazolam, triazolam or similar medicines) used to help you sleep or for anxiety</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenytoin (used for treating fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nifedipine, isradipine, amlodipine, verapamil, felodipine and losartan (for hypertension- high blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; olaparib (used for treating ovarian cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, everolimus, sirolimus or tacrolimus (to prevent transplant rejection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclophosphamide, vinca alkaloids (vincristine, vinblastine or similar medicines) used for treating cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; halofantrine (used for treating malaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statins (atorvastatin, simvastatin and fluvastatin or similar medicines) used for reducing high cholesterol levels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methadone (used for pain)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; celecoxib, flurbiprofen, naproxen, ibuprofen, lornoxicam, meloxicam, diclofenac (Non-Steroidal Anti‑Inflammatory Drugs (NSAID))</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral contraceptives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prednisone (steroid)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; zidovudine, also known as AZT; saquinavir (used in HIV-infected patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for diabetes such as chlorpropamide, glibenclamide, glipizide or tolbutamide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; theophylline (used to control asthma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tofacitinib (used for treating rheumatoid arthritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolvaptan used to treat hyponatremia (low levels of sodium in your blood) or to slow kidney function decline</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vitamin A (nutritional supplement)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ivacaftor (alone or combined with other drugs used for treating cystic fibrosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amiodarone (used for treating uneven heartbeats &lsquo;arrhythmias&rsquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hydrochlorothiazide (a diuretic)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ibrutinib (used for treating blood cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lurasidone (used to treat schizophrenia)</p><p>&nbsp;</p><p><strong>Diflucan with food and drink</strong></p><p>You can take your medicine with or without a meal.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>If you are planning to become pregnant, it is recommended to wait a week after a single dose of fluconazole before becoming pregnant.</p><p>&nbsp;</p><p>For longer courses of treatment with fluconazole, talk to your doctor on the need for appropriate contraception during treatment which should continue for one week after the last dose.</p><p>&nbsp;</p><p>You should not take Diflucan if you are pregnant, think you may be pregnant, are trying to become pregnant, unless your doctor has told you so. If you become pregnant while taking this medicine or within 1 week of the most recent dose, contact your doctor.</p><p>&nbsp;</p><p>Fluconazole taken during the first or second trimester of pregnancy may increase the risk of miscarriage. Fluconazole taken during the first trimester may increase the risk of a baby being born with birth defects affecting the heart, bones and/or muscles.</p><p>&nbsp;</p><p>There have been reports of babies born with birth defects affecting the skull, ears, and bones of the thigh and elbow in women treated for three months or more with high doses (400-800 mg daily) of fluconazole for coccidioidomycosis. The link between fluconazole and these cases is not clear.</p><p>&nbsp;</p><p>You can continue breast-feeding after taking a single dose of 150&nbsp;mg Diflucan.</p><p>&nbsp;</p><p>You should not breast-feed if you are taking a repeated dose of Diflucan.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>When driving vehicles or using machines, it should be taken into account that occasionally dizziness or fits may occur.</p><p><strong>&nbsp;</strong></p><p><strong>Diflucan contains lactose (milk sugar) </strong><strong>and </strong><strong>sodium (salt)</strong></p><p>This medicine contains a small amount of lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, please contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>Diflucan capsules contain less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take your medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Swallow the capsule whole with a glass of water. It is best to take your capsules at the same time each day.</p><p>&nbsp;</p><p>The recommended doses of this medicine for different infections are below:</p><p>&nbsp;</p><p><strong>Adults</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Condition </strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>To treat cryptococcal meningitis</p></td><td style="vertical-align:top"><p>400&nbsp;mg on the first day then 200&nbsp;mg to 400&nbsp;mg once daily for 6 to 8&nbsp;weeks or longer if needed. Sometimes doses are increased up to 800&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>To stop cryptococcal meningitis<em> </em>from coming back</p></td><td style="vertical-align:top"><p>200&nbsp;mg once daily until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To treat coccidioidomycosis</p></td><td style="vertical-align:top"><p>200&nbsp;mg to 400&nbsp;mg once daily from 11&nbsp;months for up to 24&nbsp;months or longer if needed. Sometimes doses are increased up to 800&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>To treat internal fungal infections caused by <em>Candida</em></p></td><td style="vertical-align:top"><p>800&nbsp;mg on the first day then 400&nbsp;mg once daily until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To treat mucosal infections affecting the lining of mouth, throat and denture sore mouth</p></td><td style="vertical-align:top"><p>200&nbsp;mg to 400&nbsp;mg on the first day then 100&nbsp;mg to 200&nbsp;mg once daily until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To treat mucosal thrush &ndash; dose depends on where the infection is located</p></td><td style="vertical-align:top"><p>50&nbsp;mg to 400&nbsp;mg once daily for 7 to 30&nbsp;days until you are told to stop</p></td></tr><tr><td style="vertical-align:top"><p>To stop mucosal infections affecting the lining of mouth, throat from coming back.</p></td><td style="vertical-align:top"><p>100&nbsp;mg to 200&nbsp;mg once daily, or 200&nbsp;mg 3&nbsp;times a week, while you are at risk of getting an infection</p></td></tr><tr><td style="vertical-align:top"><p>To treat genital thrush</p></td><td style="vertical-align:top"><p>150&nbsp;mg as a single dose</p></td></tr><tr><td style="vertical-align:top"><p>To reduce recurrence of vaginal thrush</p></td><td style="vertical-align:top"><p>150&nbsp;mg every third day for a total of 3&nbsp;doses (day&nbsp;1, 4 and&nbsp;7) and then once a week for 6 months while you are at risk of getting an infection</p></td></tr><tr><td style="vertical-align:top"><p>To treat fungal skin and nail infections</p></td><td style="vertical-align:top"><p>Depending on the site of the infection 50&nbsp;mg once daily, 150&nbsp;mg once weekly, 300 to 400&nbsp;mg once weekly for 1 to 4&nbsp;weeks (Athlete&rsquo;s foot may be up to 6&nbsp;weeks, for nail infection treatment until infected nail is replaced)</p></td></tr><tr><td style="vertical-align:top"><p>To stop you from getting an infection caused by <em>Candida</em> (if your immune system is weak and not working properly)</p></td><td style="vertical-align:top"><p>200&nbsp;mg to 400&nbsp;mg once daily while you are at risk of getting an infection</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Adolescents from 12 to 17&nbsp;years old</strong></p><p>Follow the dose prescribed by your doctor (either adults or children posology).</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Children to 11&nbsp;years old</strong></p><p>The maximum dose for children is 400&nbsp;mg daily.</p><p>&nbsp;</p><p>The dose will be based on the child&rsquo;s weight in kilograms.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Condition </strong></p></td><td style="vertical-align:top"><p><strong>Daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mucosal thrush and throat infections caused by <em>Candida</em> &ndash; dose and duration depends on the severity of the infection and on where the infection is located</p></td><td style="vertical-align:top"><p>3&nbsp;mg per kg of body weight once daily (6&nbsp;mg per kg of body weight might be given on the first day)</p></td></tr><tr><td style="vertical-align:top"><p>Cryptococcal meningitis or internal fungal infections caused by <em>Candida </em></p></td><td style="vertical-align:top"><p>6&nbsp;mg to 12&nbsp;mg per kg of body weight once daily</p></td></tr><tr><td style="vertical-align:top"><p>To stop cryptococcal meningitis from coming back</p></td><td style="vertical-align:top"><p>6 mg per kg of body weight once daily</p></td></tr><tr><td style="vertical-align:top"><p>To stop children from getting an infection caused by <em>Candida </em>(if their immune system is not working properly)</p></td><td style="vertical-align:top"><p>3&nbsp;mg to 12&nbsp;mg per kg of body weight once daily</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><strong>Use in children 0 to 4&nbsp;weeks of age</strong></p><p>Use in children of 3 to 4&nbsp;weeks of age:</p><p>The same dose as above but given once every 2&nbsp;days. The maximum dose is 12&nbsp;mg per kg of body weight every 48&nbsp;hours.</p><p><em>&nbsp;</em></p><p>Use in children less than 2&nbsp;weeks old:</p><p>The same dose as above but given once every 3&nbsp;days. The maximum dose is 12&nbsp;mg per kg of body weight every 72&nbsp;hours.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>The usual adult dose should be given unless you have kidney problems.</p><p>&nbsp;</p><p><strong>Patients with kidney problems</strong></p><p><strong>&nbsp;</strong></p><p>Your doctor may change your dose, depending on your kidney function.</p><p>&nbsp;</p><p><strong>How quickly will the treatment start to work? </strong></p><p><strong>&nbsp;</strong></p><p><strong>Vaginal thrush </strong></p><p>Your condition should start to clear up within a few days - some women notice an improvement in one day.</p><p>If your condition does not clear up within a few days you should go back to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Penis thrush infection </strong></p><p>Your condition should start to clear up within a few days but it may take up to a week.</p><p>If your condition has not cleared up after one week, you should go back to your doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Diflucan</strong><strong> </strong><strong>than you should</strong></p><p>Taking too many capsules at once may make you unwell. Contact your doctor or your nearest hospital casualty department at once. The symptoms of a possible overdose may include hearing, seeing, feeling and thinking things that are not real (hallucination and paranoid behaviour). Symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.</p><p>&nbsp;</p><p><strong>If you forget to take Diflucan</strong></p><p>Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the dose that you missed.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Stop taking Diflucan and seek medical attention <strong>immediately</strong> if you notice any of the following symptoms:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome)</p><p>&nbsp;</p><p>A few people develop<strong> allergic reactions </strong>although serious allergic reactions are rare<strong>. </strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. If you get any of the following symptoms,<strong> tell </strong><strong>your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheezing, difficulty in breathing or tightness in the chest</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of eyelids, face or lips</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching all over the body reddening of the skin or itchy red spots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions such as a rash that causes blistering (this can affect the mouth and tongue).</p><p>&nbsp;</p><p>Diflucan may affect your liver. The signs of liver problems include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of your skin or the whites of your eyes (jaundice)</p><p>&nbsp;</p><p>If any of these happen, stop taking Diflucan and <strong>tell your doctor immediately.</strong></p><p>&nbsp;</p><p><strong>Other side effects:</strong></p><p>Additionally, if any of the following side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people) are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort, diarrhoea, feeling sick, vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases in blood tests of liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people) are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make skin pale and cause weakness or breathlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to sleep, feeling drowsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fit, dizziness, sensation of spinning, tingling, pricking or numbness, changes in sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, difficult digestion, wind, dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver damage and yellowing of the skin and eyes (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheals, blistering (hives), itching, increased sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, general feeling of being unwell, fever</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people) are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower than normal white blood cells that help defend against infections and blood cells that help to stop bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red or purple discoloration of the skin which may be caused by low platelet count, other blood cell changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood chemistry changes (high blood levels of cholesterol, fats)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood potassium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shaking</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal electrocardiogram (ECG), change in heart rate or rhythm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (sometimes severe), including widespread blistering rash and skin peeling, severe skin reactions, swelling of the lips or face</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>Frequency not known, but may occur (cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reaction with skin rash, fever, swollen glands, increase in a type of white blood cell (eosinophilia) and inflammation of internal organs (liver, lungs, heart, kidneys and large intestine) (Drug Reaction or rash with Eosinophilia and Systemic Symptoms (DRESS))</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>-&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>-&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shelf life: 60 months.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is fluconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each hard capsule contains 50&nbsp;mg, 150&nbsp;mg or 200&nbsp;mg<strong> </strong>of fluconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><strong>&nbsp;</strong></p><p><strong>Capsule content:</strong> lactose monohydrate, maize starch, colloidal silica anhydrous, magnesium stearate and sodium lauryl Sulfate (see section 2, Diflucan contains lactose (milk sugar) and sodium (salt)).</p><p>&nbsp;</p><p><strong>Capsule shell composition:</strong></p><p><strong>50&nbsp;mg hard capsules</strong>: gelatin, titanium dioxide and patent blue.</p><p><strong>150&nbsp;mg hard capsules: </strong>gelatin, titanium dioxide&nbsp;and patent blue&nbsp;</p><p><strong>200&nbsp;mg hard capsules: </strong>gelatin, titanium dioxide, erythrosine and indigo carmine&nbsp;</p><p><u>&nbsp;</u></p><p><strong>Printing ink:</strong> shellac (glaze), black iron oxide, N-Butyl alcohol, dehydrated alcohol, purified water, propylene glycol, industrial methylated spirit, isopropyl alcohol, strong ammonia solution, potassium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -	Diflucan 50 mg hard capsules have a white body and a turquoise blue cap. They have “FLU 50” and “Pfizer” with black ink printed on them.
-	Diflucan 150 mg hard capsules have a turquoise blue body and a turquoise blue cap. They have “FLU 150” and “Pfizer” with black ink printed on them.
-	Diflucan 200 mg hard capsules have a white body and a purple cap. They have “FLU 200” and “Pfizer” with black ink printed on them. 

Diflucan 150 mg: Each pack contains 1 capsule.
Diflucan 50mg and 200 mg: Each pack contains 7 capsules


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p><strong>PFIZER HOLDING FRANCE</strong></p><p>23-25, AVENUE DU DOCTEUR LANNELONGUE</p><p>75014 PARIS, FRANCE</p><p>&nbsp;</p><p><strong>Manufacturer</strong><strong><u> </u></strong></p><p>FAREVA AMBOISE&nbsp;</p><p>ZONE INDUSTRIELLE</p><p>29 ROUTE DES INDUSTRIES</p><p>37530 POCE-SUR-CISSE, FRANCE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ديفلوكان لمجموعة من الأدوية تُدعى &quot;مُضادات الفطريات&quot;. المادة الفعالة هي فلوكونازول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم ديفلوكان &nbsp;لعلاج العدوى التي تسببها الفطريات وقد يُستخدم كذلك لمنع إصابتك بعدوى المُبيضات. أكثر مسببات العدوى الفطرية شيوعًا هي خميرة يُطلق عليها المُبيضة (كانديدا).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">قد يصف لك طبيبك هذا الدواء لعلاج أنواع العدوى الفطرية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lrm;التهاب السحايا بالمستخفيات ــ عدوى فطرية في الدماغ،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى الصحراء (الفطار الكرواني) ــ مرض يصيب الجهاز القصبي الرئوي،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تسببها المُبيضة (كانديدا)، والتي تظهر بمجرى الدم أو الأعضاء (مثل، القلب أو الرئتين) أو المسالك البولية،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلاع مخاطي ــ عدوى تُصيب بطانة الفم والحلق والتهاب الفم تحت تركيبات الأسنان الصناعية،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلاع التناسلي ــ عدوى تصيب المهبل أو القضيب،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد ــ مثل، قدم الرياضي أو السعفة أو حِكَّة اللَّعِب (سعفة الفخذ) أو عدوى الأظفار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يوصف لك ديفلوكان كذلك من أجل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من تكرار الإصابة بالتهاب السحايا بالمستخفيات،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من تكرار الإصابة بالقلاع المخاطي،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد من تكرار الإصابة بالقلاع المهبلي،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الإصابة بعدوى تسببها المُبيضة (كانديدا) (إذا كان جهازك المناعي ضعيفًا أو لا يعمل بشكلٍ جيد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong>(<strong>٠ إلى ١٧ عامًا</strong>)</p><p dir="RTL">قد يصف لك طبيبك هذا الدواء لعلاج أنواع العدوى الفطرية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلاع المخاطي ــ عدوى تُصيب بطانة الفم والحلق،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تسببها المُبيضة (كانديدا) والتي تظهر بمجرى الدم أو أعضاء الجسم (مثل، القلب والرئتين) أو المسالك البولية،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lrm;التهاب السحايا بالمستخفيات ــ عدوى فطرية في الدماغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يوصف لك ديفلوكان كذلك من أجل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع إصابتك بعدوى تسببها المبيضة (كانديدا) (إذا كان جهازك المناعي ضعيفًا أو لا يعمل بشكلٍ جيد)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع التهاب السحايا بالمستخفيات من العودة مجددًا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال ديفلوكان </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه فلوكونازول أو أي أدوية أخرى تناولتها لعلاج العدوى الفطرية أو تجاه أي مكونات أخرى في هذا الدواء (مُدرجة في القسم ٦). قد تتضمن الأعراض حكة، أو احمرار الجلد، أو صعوبة في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أستيميزول أو تيرفينادين (أدوية مضادة للهيستامين لعلاج الحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول سيسابريد (يستخدم لعلاج متاعب المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول بيموزيد (يستخدم لعلاج الأمراض العقلية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول كينيدين (يستخدم لعلاج اضطراب ضربات القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول إريثروميسين (مضاد حيوي لعلاج العدوى)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال ديفلوكان</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول ديفلوكان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكبد أو الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض في القلب، بما في ذلك المشكلات في ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت مستويات البوتاسيوم أو الكالسيوم أو المغنيسيوم بالدم غير طبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بتفاعلات جلدية شديدة (الحكة أو احمرار الجلد أو صعوبة التنفس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت لديك علامات قصور كظري &quot; حيث لا تنتج الغدد الكظرية كميات كافية من بعض الهرمونات الستيرويدية مثل الكورتيزول (الإرهاق المزمن أو الذي يستمر لفترات طويلة، وضعف العضلات، وفقدان الشهية، وفقدان الوزن، وألم البطن)،</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت قد أصبت من قبل بعرض واحد على الأقل من الأعراض التالية بعد تناول فلوكونازول: طفح أو تقشر جلدي شديد، أو بثور، أو قرح في الفم</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ عن حدوث تفاعلات جدلية خطيرة بما في ذلك التفاعلات الدوائية المصحوبة بكثرة اليوزينيات والأعراض الجهازية (DRESS) فيما يتعلق بالعلاج بفلوكونازول. توقف عن تناول ديفلوكان واطلب العناية الطبية على الفور إذا لاحظت أيًا من الأعراض المرتبطة بهذه التفاعلات الجلدية الخطيرة الموصوفة في القسم ٤.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي إذا لم تتحسن حالة العدوى الفطرية، فقد تكون هناك حاجة إلى استخدام علاج بديل مضاد للفطريات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك <strong>على الفور</strong> إذا كنت تتلقى أستيميزول أو تيرفينادين (دواء مضاد للهيستامين لعلاج الحساسية) أو سيسابريد (الذي يستخدم لعلاج متاعب المعدة) أو بيموزيد (الذي يستخدم لعلاج الأمراض العقلية) أو كينيدين (الذي يستخدم لعلاج اضطراب نظم ضربات القلب) أو إريثروميسين (مضاد حيوي لعلاج العدوى) حيث يُحظر تناول هذه الأدوية في نفس الوقت مع ديفلوكان (&quot;موانع استعمال ديفلوكان&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتفاعل بعض الأدوية مع ديفلوكان. احرص على إخبار طبيبك إذا كنت تتناول أيًا من الأدوية التالية &rlm; حيث قد يلزم&nbsp; تعديل الجرعة أو المراقبة للتحقق من أن الادوية لا تزال تحقق التأثير المطلوب:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين أو ريفابوتين (مضادات حيوية لعلاج العدوى)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>أبروسيتينيب (يُستخدم لعلاج </em>التهاب الجلد التأتبي، المعروف أيضًا بالإكزيما التأتبية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل، فينتانيل (يستخدم كمادة مخدرة)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميتريبتيلين، نورتريبتيلين (تستخدم كمضادات للاكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتريسين ب، فوريكونازول (مضاد للفطريات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعمل على تسييل الدم لمنع تكون جلطات الدم (وارفارين أو الأدوية المشابهة)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنزوديازيبينات (ميدازولام أو تريازولام أو الأدوية المشابهة) التي تستخدم لمساعدتك على النوم أو للحد من القلق،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، فينيتوين (التي تستخدم لعلاج النوبات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفيديبين وإسراديبين وأملوديبين وفيراباميل وفيلوديبين ولوسارتان (تستخدم لعلاج ارتفاع ضغط الدم - ضغط الدم المرتفع)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أولاباريب (يستخدم لعلاج سرطان المبيض)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين أو ايفيروليموس أو سيروليموس أو تاكروليموس (لمنع رفض الأجزاء المزروعة)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سايكلوفوسفاميد، قلويدات الفينكا (فينكريستين أو فينبلاستين أو الأدوية المشابهة) التي تستخدم لعلاج السرطان،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين (يستخدم لعلاج الملاريا)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات (أتورفاستاتين أو سيمفاستاتين أو فلوفاستاتين أو الأدوية المشابهة) التي تستخدم لخفض مستويات الكوليسترول المرتفعة،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثادون (يستخدم لتخفيف الآلام)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيليكوكسيب، فلوربيبروفين، نابروكسين، إيبوبروفين، لورنوكسيكام، ميلوكسيكام، ديكلوفيناك (مضادات الالتهاب غير الستيرويدية (NSAID))،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل التي تؤخذ عبر الفم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بريدنيزون (من الستيرويدات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفودين، المعروف كذلك باسم AZT؛ ساكينافير (يستخدم لعلاج المرضى المصابين بعدوى فيروس نقص المناعة البشرية (HIV))،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج السكري مثل، كلوربروباميد أو جليبينكلاميد أو جليبيزيد أو تولبوتاميد،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيلين (يستخدم للتحكم في الربو)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توفاسيتينيب&nbsp;(يستخدم لعلاج التهاب المفاصل الروماتويدي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولفابتان يستخدم لعلاج نقص صوديوم الدم (انخفاض مستويات الصوديوم في دمك) أو للحد من تدهور وظائف للكلى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيتامين أ (مكمل غذائي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفاكافتور (يستخدم بمفرده أو مع أدوية أخرى لعلاج التليف الكيسي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميودارون (يستخدم لعلاج اضطراب نبض القلب &quot;اضطرابات نظم ضربات القلب&quot;)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكلوروثيازيد (مدر للبول)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبروتينيب (يستخدم لعلاج سرطان الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوراسيدون (يستخدم لعلاج انفصام الشخصية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول ديفلوكان مع الطعام والشراب</strong></p><p dir="RTL">يُمكنك تناول هذا الدواء مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنك ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ تخططين للحمل، فإنه يوصى بالانتظار لمدة أسبوع بعد تناول جرعة فردية من فلوكونازول قبل أن تصبحي حاملًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لبرامج العلاج الأطول بفلوكونازول، تحدثي إلى طبيبكِ عن الحاجة إلى وسيلة ملائمة لمنع الحمل في أثناء العلاج وينبغي أن يستمر استعمالها لمدة أسبوع واحد بعد آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليكِ عدم تناول ديفلوكان إذا كنتِ حاملًا أو تعتقدين أنك ربما تكونين حاملًا أو تخططين للإنجاب أو تحاولين أن تصبحي حاملًا إلا إذا أخبركِ الطبيب أنه من الآمن القيام بذلك. إذا أصبحتي حاملًا أثناء تناولكِ هذا الدواء أو في الأسبوع الذي يلي تناولكِ آخر جرعة، تواصلي مع الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تناول فلوكونازول خلال الثلث الأول أو الثاني من الحمل قد يزيد من خطر التعرض للإجهاض. وتناوله خلال الثلث الأول من الحمل قد يؤدي إلى زيادة في خطر ولادة طفل بعيوب خلقية تؤثر على القلب أو العظام أو العضلات أو جميعها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أُبلغ عن ولادة أطفال بعيوب خلقية تؤثر على الجمجمة والأذنين وعظام الفخذ والمرفق لدى السيدات اللاتي عولجن لمدة ثلاثة أشهر أو أكثر بجرعات عالية (٤٠٠-٨٠٠ ملجم يوميًا) من فلوكونازول لعلاج حمى الصحراء (الفطار الكرواني). العلاقة بين فلوكونازول وهذه الحالات غير واضحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنكِ الاستمرار في الإرضاع رضاعة طبيعية بعد تناول جرعة فردية من ديفلوكان تبلغ ١٥٠ ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عليكِ عدم الإرضاع رضاعة طبيعية إذا كنتِ تتناولين جرعة متكررة من ديفلوكان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير ديفلوكان على القيادة واستخدام الآلات</strong></p><p dir="RTL">عند قيادة المركبات أو استخدام الآلات، ينبغي أن تضع في الحسبان إمكانية حدوث دوار أو نوبات صرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات ديفلوكان</strong></p><p dir="RTL"><strong>يحتوي ديفلوكان على اللاكتوز (سكر اللبن) والصوديوم (الملح)</strong></p><p dir="RTL">يحتوي هذا الدواء على كمية صغيرة من اللاكتوز (سكر اللبن). إذا أخبرك طبيبك أنك لا تستطيع تحمل بعض أنواع السكريات، يُرجى الاتصال به قبل تناول هذا الدواء.</p><p dir="RTL">تحتوي كبسولات ديفلوكان على أقل من ١ مليمول (٢٣) من الصوديوم في كل كبسولة، بعبارة أخرى &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. ينبغي أن تتحقق من طبيبك أو الصيدلي إذا لم تكن متأكدًا مما عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بابتلاع الكبسولة بالكامل مع شرب كوب ماء. من الأفضل تناول الكبسولات في نفس التوقيت كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعات الموصى بها لهذا الدواء لدواعي الاستعمال المتعددة مدرجة أدناه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الحالة </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج التهاب السحايا بالمستخفيات</p></td><td style="vertical-align:top"><p dir="RTL">٤٠٠ ملجم في اليوم الأول ثم ٢٠٠ ملجم إلى ٤٠٠ ملجم مرة يوميًا لمدة ٦ إلى ٨ أسابيع أو أكثر إذا لزم الأمر. في بعض الأحيان تزيد الجرعة إلى ٨٠٠ ملجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لمنع التهاب السحايا بالمستخفيات من العودة مجددًا</p></td><td style="vertical-align:top"><p dir="RTL">٢٠٠ ملجم مرة يوميًا حتى تلقيك تعليمات بوقفه</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج حمى الصحراء (الفطار الكرواني)</p></td><td style="vertical-align:top"><p dir="RTL">٢٠٠ ملجم إلى ٤٠٠ ملجم مرة يوميًا لمدة تتراوح ما بين ١١ إلى ٢٤ شهرًا أو أكثر إذا لزم الأمر. في بعض الأحيان تزيد الجرعة إلى ٨٠٠ ملجم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج العدوى الفطرية الداخلية التي تسببها المُبيضة (كانديدا)</p></td><td style="vertical-align:top"><p dir="RTL">٨٠٠ ملجم في اليوم الأول ثم ٤٠٠ ملجم مرة يوميًا حتى تلقيك تعليمات بوقفه</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج عدوى بطانة الفم والحلق والتهاب الفم&nbsp; تركيبات الأسنان الصناعية</p></td><td style="vertical-align:top"><p dir="RTL">٢٠٠ ملجم إلى ٤٠٠ ملجم في اليوم الأول ثم ١٠٠ ملجم إلى ٢٠٠ ملجم مرة يوميًا إلى أن تتلقى تعليمات بوقفه</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج القلاع المخاطي - تعتمد الجرعة على موضع العدوى</p></td><td style="vertical-align:top"><p dir="RTL">٥٠ ملجم إلى ٤٠٠ ملجم مرة يوميًا لمدة تتراوح ما بين ٧ أيام ٣٠ يومًا إلى أن تتلقى تعليمات بوقفه</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لمنع تكرار ظهور عدوى بطانة الفم والحلق.</p></td><td style="vertical-align:top"><p dir="RTL">١٠٠ ملجم إلى ٢٠٠ ملجم مرة يوميًا، أو ٢٠٠ ملجم ٣ مرات أسبوعيًا عندما يكون هناك خطر للإصابة بعدوى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج القلاع التناسلي</p></td><td style="vertical-align:top"><p dir="RTL">١٥٠ ملجم كجرعة فردية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الحد من &nbsp;تكرر الإصابة بالقلاع المهبلي</p></td><td style="vertical-align:top"><p dir="RTL">١٥٠ ملجم كل ثلاثة أيام من إجمالي ٣ جرعات (يوم ١ و٤ و٧)، ثم مرة أسبوعيًا لمدة ٦ أشهر عندما يكون هناك خطر للإصابة بعدوى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لعلاج العدوى الفطرية التي تصيب الجلد والأظافر</p></td><td style="vertical-align:top"><p dir="RTL">اعتمادًا على موقع العدوى تكون الجرعة ٥٠ ملجم مرة يوميًا، أو ١٥٠ ملجم مرة أسبوعيًا، أو ٣٠٠ ملجم إلى ٤٠٠ ملجم مرة أسبوعيًا لمدة تتراوح ما بين أسبوع إلى ٤ أسابيع (قد تصل فترة علاج قدم الرياضي إلى ٦ أسابيع وبالنسبة لعلاج عدوى الأظفار يستمر العلاج حتى استبدال الظفر المصاب)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الوقاية من الإصابة بعدوى تسببها المُبيضة (كانديدا) (إذا كان جهازك المناعي ضعيفًا أو لا يعمل بشكلٍ جيد)</p></td><td style="vertical-align:top"><p dir="RTL">٢٠٠ إلى ٤٠٠ ملجم مرة يوميًا عندما يكون هناك خطر للإصابة بعدوى</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراهقون من</strong> <strong>١٢</strong> <strong>إلى</strong> <strong>١٧</strong> <strong>عامًا</strong></p><p dir="RTL">اتبع الجرعة التي وصفها لك طبيبك (سواء المخصصة للبالغين أو الأطفال).</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الأطفال حتى</strong> <strong>١١</strong> <strong>عامًا</strong></p><p dir="RTL">يبلغ الحد الأقصى للجرعة للأطفال ٤٠٠ ملجم يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستعتمد الجرعة على وزن الطفل بالكيلو غرام.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الحالة </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة اليومية</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">القلاع المخاطي وعدوى الحلق التي تسببها المُبيضة (كانديدا)- تعتمد الجرعة والمدة على شدة العدوى ومكانها</p></td><td style="vertical-align:top"><p dir="RTL">٣ ملجم لكل كلجم من وزن الجسم مرة يوميًا (قد يتم إعطاء ٦ ملجم لكل كلجم من وزن الجسم في اليوم الأول)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب السحايا بالمستخفيات أو العدوى الفطرية الداخلية التي تسببها المُبيضة (كانديدا)</p></td><td style="vertical-align:top"><p dir="RTL">٦ ملجم إلى ١٢ ملجم لكل كلجم من وزن الجسم مرة يوميًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لمنع التهاب السحايا بالمستخفيات من العودة مجددًا</p></td><td style="vertical-align:top"><p dir="RTL">٦ ملجم لكل كلجم من وزن الجسم مرة يوميًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">وقاية الأطفال من الإصابة بعدوى تسببها المُبيضة (كانديدا) (إذا كان جهازهم المناعي ضعيفًا أو لا يعمل بشكلٍ جيد)</p></td><td style="vertical-align:top"><p dir="RTL">٣ ملجم إلى ١٢ ملجم لكل كلجم &nbsp;من وزن الجسم مرة يوميًا</p></td></tr></tbody></table><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الاستخدام مع الأطفال من</strong> <strong>٠</strong> <strong>إلى</strong> <strong>٤</strong> <strong>أسابيع من العمر</strong></p><p dir="RTL">الاستخدام مع الأطفال من ٣ إلى ٤ أسابيع من العمر:</p><p dir="RTL">نفس الجرعة المذكورة أعلاه ولكن تُعطى مرة كل يومين. الحد الأقصى للجرعة ١٢ ملجم لكل كج من وزن الجسم وذلك كل ٤٨ ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاستخدام مع الأطفال الذين يقل عمرهم عن أسبوعين:</p><p dir="RTL">نفس الجرعة المذكورة أعلاه ولكن تُعطى مرة كل ثلاثة&nbsp;أيام. الحد الأقصى للجرعة ١٢&nbsp;ملجم لكل كج من وزن الجسم وذلك كل ٧٢&nbsp;ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المسنون</strong></p><p dir="RTL">ينبغي أن تُعطى نفس الجرعة الخاصة بالبالغين ما لم تكن تعاني من مشكلات بالكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من مشكلات بالكلى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يقوم طبيبك بتغيير الجرعة التي تتلقاها وفقًا لحالة وظائف الكلى لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما مدى سرعة بدء العلاج في العمل؟</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القلاع المهبلي</strong></p><p dir="RTL"><u>يفترض أن تبدأ حالتكِ في الشفاء في غضون بضعة أيام &ndash; تلاحظ بعض السيدات تحسنًا في يوم واحد.</u></p><p dir="RTL"><u>إذا لم تختفي حالتكِ في غضون بضعة أيام، فينبغي لكِ العودة إلى طبيبكِ.</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong><u>عدوى القلاع في القضيب</u></strong></p><p dir="RTL"><u>يفترض</u> أن تبدأ حالتك في الشفاء <u>في غضون بضعة أيام، ولكن قد يستغرق الأمر ما يصل إلى أسبوع.</u></p><p dir="RTL"><u>إذا لم تختفي حالتك بعد أسبوع واحد، فينبغي لك العودة إلى طبيبك.</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من</strong> <strong>ديفلوكان</strong></p><p dir="RTL">إن تناولك للعديد من الكبسولات في آن واحد قد يسبب لك المرض. اتصل بطبيبك أو بقسم الإصابات في أقرب مستشفى على الفور. قد تتضمن أعراض الجرعة المفرطة المحتملة سماع أو رؤية أو الشعور بأشياء غير حقيقية أو التفكير بها (الهلوسة والسلوك الارتيابي (البارانوي)). قد يكون علاج الأعراض (مع تطبيق التدابير الداعمة وإجراء غسيل للمعدة إذا لزم الأمر) كافيًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نسيان تناول جرعة ديفلوكان</strong></p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض جرعة منسية. إذا نسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرها. إذا كان موعد جرعتك التالية قد أوشك، فلا تتناول الجرعة التي نسيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كان لديك المزيد من الأسئلة بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقف عن تناول ديفلوكان واطلب العناية الطبية <strong>على الفور </strong>إذا لاحظت أي من الأعراض التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار، وارتفاع درجة حرارة الجسم، وتضخم العقد الليمفاوية (متلازمة التفاعلات الدوائية المصحوبة بكثرة اليوزينيات والأعراض الجهازية أو متلازمة فرط الحساسية الدوائية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">يصاب عدد ضئيل من الأشخاص <strong>بتفاعلات حساسية</strong>، بالرغم من ندرة حدوث تفاعلات الحساسية الخطيرة. إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة لم يرد ذكرها في هذه النشرة. في حالة إصابتك بأي من الأعراض التالية، <strong>أخبر </strong><strong>طبيبك على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحالات المفاجئة من الأزيز، أو صعوبة التنفس، أو ضيق في الصدر،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون، أو الوجه، أو الشفتين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بحكة في جميع أنحاء الجسم، أو احمرار الجلد، أو ظهور بقع حمراء مسببة للحكة،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية الشديدة، مثل الطفح الجلدي الذي يسبب تقرحات (قد تصيب الفم واللسان).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر ديفلوكان على كبدك. تتضمن علامات وجود مشكلات بالكبد ما يلي:</p><p dir="RTL">الإعياء-&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو الأجزاء البيضاء من العينين (يرقان)</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة حدوث أي من هذه الأعراض، توقف عن تناول ديفلوكان <strong>وأخبر طبيبك على الفور</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأخرى:</strong></p><p dir="RTL">إضافة إلى ذلك، إذا ما تفاقمت شدة أي من الآثار الجانبية التالية بشكل خطير، أو إذا لاحظت ظهور أي آثار جانبية غير واردة في هذه النشرة، يرجى إخبار طبيبك أو الصيدلي بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد بين كل ١٠ أشخاص) هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالمعدة، إسهال، غثيان، قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادات في نتائج فحوصات الدم الخاصة بوظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تصيب ما يصل إلى شخص واحد بين كل ١٠٠ شخص) هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في تعداد خلايا الدم الحمراء الذي قد يتسبب في شحوب لون الجلد ويسبب الضعف أو عدم القدرة على التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم، الشعور بالنعاس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات، دوار، شعور بدوخة، وخز، نخز أو تنميل، تغيرات في حاسة التذوق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، صعوبة الهضم، امتلاء البطن بالغازات، جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الكبد واصفرار الجلد والعينين (يرقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثرات، ظهور تقرحات (انتبارات)، حكة، زيادة العرق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء، شعور عام بالتوعك، حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية النادرة (قد تصيب ما يصل إلى شخص واحد بين كل ١٠٠٠ شخص) هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عن المعدل الطبيعي في تعداد خلايا الدم البيضاء التي تساعد في حماية الجسم من العدوى وخلايا الدم التي تساعد على وقف النزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون الجلد إلى اللون الأحمر أو الأرجواني والذي قد ينتج عن انخفاض تعداد الصفيحات الدموية، تغيرات أخرى في خلايا الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كيمياء الدم (ارتفاع مستويات الكوليسترول، أو الدهون في الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة البوتاسيوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعشة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لرسم القلب (ECG)، تغير في معدل أو نظم ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (أحيانًا ما تكون شديدة)، بما في ذلك تقشر الجلد والطفح الجلدي التقرحي المنتشر، تفاعلات جلدية شديدة، تورم الشفتين أو الوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&nbsp;</p><p dir="RTL">معدل التكرار غير معروف، لكن يمكن أن تحدث (لا يمكن تقديرها من البيانات المتاحة):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط التحسس المصحوبة بطفح جلدي، وحمى، وتورم الغدد، وزيادة في أحد أنواع خلايا الدم البيضاء (كثرة اليوزينيات)، والتهاب الأعضاء الداخلية (الكبد والرئتين والقلب والكليتين والأمعاء الغليظة) (التفاعلات الدوائية أو الطفح الجلدي المصحوبين بكثرة اليوزينيات وأعراض جهازية (DRESS))</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>الإبلاغ عن الأعراض الجانبية </u></strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة لم يرد ذكرها في هذه النشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن أي عرض (أعراض) جانبي:</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: ١٩٩٩٩</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صلاحية المستحضر: ٦٠ شهرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على العبوة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في درجة حرارة أقل من ٣٠ درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة فلوكونازول.</p><p dir="RTL">تحتوي كل كبسولة صلبة على ٥٠ أو ١٥٠ أو ٢٠٠ ملجم من فلوكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>محتوى الكبسولة: </strong></p><p dir="RTL">لاكتوز أحادي الهيدرات، ونشا الذرة، والسيليكا الغروانية اللامائية، وستيارات المغنيسيوم، ولوريل كبريتات الصوديوم (انظر القسم ٢، يحتوي ديفلوكان على اللاكنوز (سكر اللبن) والصوديوم (الملح)).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مكونات غلاف الكبسولة:</strong></p><p dir="RTL"><strong>كبسولات</strong> <strong>٥٠</strong> <strong>ملجم صلبة</strong>: جيلاتين، وثاني أكسيد التيتانيوم ، وصبغة طعام زرقاء</p><p dir="RTL"><strong>كبسولات</strong> <strong>١٥٠</strong> <strong>ملجم صلبة</strong>: جيلاتين، وثاني أكسيد التيتانيوم ، وصبغة طعام زرقاء</p><p dir="RTL"><strong>كبسولات</strong> <strong>٢٠٠</strong> <strong>ملجم صلبة</strong>:<strong> </strong>جيلاتين، وثاني أكسيد التيتانيوم ، وإريثروسين ، وصبغة نيلية قرمزية</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>حبر الطباعة: </strong></p><p dir="RTL">صمغ اللك (الطبقة اللامعة)، وأكسيد الحديد الأسود، وكحول ن-بيوتيلي، والكحول المجفف، والماء المنقى، وبروبيلين جليكول، والكحول المميثل الصناعي، وكحول أيزوبروبيلي، ومحلول أمونيا قوي، وهيدروكسيد البوتاسيوم</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات ديفلوكان ٥٠ ملجم الصلبة لها جسم أبيض وغطاء أزرق فيروزي. مطبوع على الكبسولات كلمتا &quot;FLU50&quot; و&quot;Pfizer&quot; بالحبر الأسود.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة ديفلوكان ١٥٠ ملجم الصلبة لها جسم أزرق فيروزي وغطاء من نفس اللون. مطبوع على الكبسولات كلمتا &quot;FLU150&quot; و&quot;Pfizer&quot; بالحبر الأسود.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات ديفلوكان ٢٠٠ ملجم الصلبة لها جسم أبيض وغطاء أرجواني. مطبوع على الكبسولات كلمتا &quot;FLU200&quot; و&quot;Pfizer&quot; بالحبر الأسود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُطرح ديفلوكان ١٥٠ ملجم في عبوات تحتوي على كبسولة واحدة.</p><table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُطرح ديفلوكان ٥٠ ملجم و٢٠٠ ملجم في عبوات تحتوي على ٧ كبسولات.</p></td></tr></tbody></table></td></tr></tbody></table><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>الشركة المسوقة</u></strong></p><p><strong>PFIZER HOLDING FRANCE</strong></p><p>23-25, AVENUE DU DOCTEUR LANNELONGUE</p><p>75014 PARIS, FRANCE</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>المصنع</u></strong></p><p><strong>FAREVA AMBOISE</strong></p><p>ZONE INDUSTRIELLE</p><p>29 ROUTE DES INDUSTRIES</p><p>37530 POCE-SUR-CISSE, FRANCE</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس/آذار ٢٠٢٤.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diflucan 50 mg hard capsules
Diflucan 150 mg hard capsules
Diflucan 200 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains fluconazole 50 mg
Excipient(s) with known effects: each hard capsule also contains 49.70 mg lactose monohydrate.

Each hard capsule contains fluconazole 150 mg
Excipient(s) with known effects: each hard capsule also contains 149.12 mg lactose monohydrate

Each hard capsule contains fluconazole 200 mg
Excipient(s) with known effects: each hard capsule also contains 198.82 mg lactose monohydrate

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

The 50 mg hard gelatin capsule has a white body and a turquoise blue cap overprinted with “Pfizer” and the code “FLU 50” with black ink. The capsule size is no. 4.

The 150 mg hard gelatin capsule has a turquoise blue body and turquoise blue cap overprinted with “Pfizer” and the code “FLU 150” with black ink. The capsule size is no. 1.

The 200 mg hard gelatin capsule has a white body and a purple cap overprinted with “Pfizer” and the code “FLU 200” with black ink. The capsule size is no. 0.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diflucan is indicated in the following fungal infections (see section 5.1).</p><p>&nbsp;</p><p><u>Diflucan is indicated in adults for the treatment of:</u></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cryptococcal meningitis (see section 4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coccidioidomycosis (see section 4.4).</p><p>&middot;&nbsp;&nbsp; Invasive candidiasis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.</p><p>&middot;&nbsp;&nbsp; Candidal balanitis when local therapy is not appropriate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dermatomycosis including <em>tinea pedis</em>, <em>tinea corporis</em>, <em>tinea cruris</em>, <em>tinea versicolor</em> and dermal <em>candida</em> infections when systemic therapy is indicated.</p><p>&middot;&nbsp;&nbsp; <em>Tinea unguinium (onychomycosis)</em> when other agents are not considered appropriate.</p><p>&nbsp;</p><p><u>Diflucan is indicated in adults for the prophylaxis of:</u></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Relapse of cryptococcal meningitis in patients with high risk of recurrence.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation (see section 5.1)).</p><p>&nbsp;</p><p><u>Diflucan is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:</u></p><p>&nbsp;</p><p>Diflucan is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Diflucan can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence (see section 4.4).</p><p>Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti‑infective therapy should be adjusted accordingly.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antifungals.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Indications</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Posology</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Duration of treatment</u></strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cryptococcosis</strong></p></td><td style="vertical-align:top"><p>- Treatment of cryptococcal meningitis.</p></td><td style="vertical-align:top"><p>Loading dose: 400&nbsp;mg on Day&nbsp;1</p><p>Subsequent dose: 200&nbsp;mg to 400&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>Usually at least 6 to 8&nbsp;weeks.</p><p>In life threatening infections the daily dose can be increased to 800&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>- Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with high risk of recurrence.</p></td><td style="vertical-align:top"><p>200&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>Indefinitely at a daily dose of 200&nbsp;mg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Coccidioidomycosis</strong><strong> </strong></p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>200&nbsp;mg to 400&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>11&nbsp;months up to 24&nbsp;months or longer depending on the patient. 800&nbsp;mg daily may be considered for some infections and especially for meningeal disease</p></td></tr><tr><td style="vertical-align:top"><p><strong>Invasive candidiasis </strong></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Loading dose: 800&nbsp;mg on Day&nbsp;1</p><p>Subsequent dose: 400&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>In general, the recommended duration of therapy for candidemia is for 2&nbsp;weeks after first negative blood culture result and resolution of signs and symptoms attributable to candidemia.</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Treatment of mucosal candidiasis</strong></p></td><td style="vertical-align:top"><p>- Oropharyngeal candidiasis</p></td><td style="vertical-align:top"><p>Loading dose: 200&nbsp;mg to 400&nbsp;mg on Day&nbsp;1</p><p>Subsequent dose: 100&nbsp;mg to 200&nbsp;mg once daily</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>7 to 21&nbsp;days (until oropharyngeal candidiasis is in remission).</p><p>Longer periods may be used in patients with severely compromised immune function</p></td></tr><tr><td style="vertical-align:top"><p>- Oesophageal candidiasis</p></td><td style="vertical-align:top"><p>Loading dose: 200&nbsp;mg to 400&nbsp;mg on Day&nbsp;1</p><p>Subsequent dose: 100&nbsp;mg to 200&nbsp;mg once daily</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>14 to 30&nbsp;days (until oesophageal candidiasis is in remission).</p><p>Longer periods may be used in patients with severely compromised immune function</p></td></tr><tr><td style="vertical-align:top"><p>- Candiduria</p></td><td style="vertical-align:top"><p>200&nbsp;mg to 400&nbsp;mg once daily</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>7 to 21&nbsp;days. Longer periods may be used in patients with severely compromised immune function.</p></td></tr><tr><td style="vertical-align:top"><p>- Chronic atrophic candidiasis</p></td><td style="vertical-align:top"><p>50&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>14&nbsp;days</p></td></tr><tr><td style="vertical-align:top"><p>- Chronic mucocutaneous candidiasis</p></td><td style="vertical-align:top"><p>50&nbsp;mg to 100&nbsp;mg once daily</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Up to 28&nbsp;days. Longer periods depending on both the severity of infection or underlying immune compromisation and infection</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Prevention of relapse of mucosal candidiasis in patients infected with HIV who are at high risk of experiencing relapse</strong></p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>- Oropharyngeal candidiasis</p></td><td style="vertical-align:top"><p>100&nbsp;mg to 200&nbsp;mg once daily or 200&nbsp;mg 3&nbsp;times per week</p></td><td style="vertical-align:top"><p>An indefinite period for patients with chronic immune suppression</p></td></tr><tr><td style="vertical-align:top"><p>- Oesophageal candidiasis</p></td><td style="vertical-align:top"><p>100&nbsp;mg to 200&nbsp;mg once daily or 200&nbsp;mg 3&nbsp;times per week</p></td><td style="vertical-align:top"><p>An indefinite period for patients with chronic immune suppression</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Genital candidiasis</strong></p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>- Acute vaginal candidiasis</p><p>- Candidal balanitis</p></td><td style="vertical-align:top"><p>150&nbsp;mg</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Single dose</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- Treatment and prophylaxis of recurrent vaginal candidiasis (4 or more episodes a year).</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>150&nbsp;mg every third day for a total of 3 doses (day 1, 4, and 7) followed by 150&nbsp;mg once weekly maintenance dose</p></td><td style="vertical-align:top"><p>&nbsp;Maintenance dose: 6&nbsp;months.</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Dermatomycosis</strong></p></td><td style="vertical-align:top"><p><em>- tinea pedis,</em></p><p><em>- tinea corporis,</em></p><p><em>- tinea cruris,</em></p><p>- <em>candida </em>infections</p></td><td style="vertical-align:top"><p>150&nbsp;mg once weekly or 50&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>2 to 4&nbsp;weeks, <em>tinea pedis</em> may require treatment for up to 6&nbsp;weeks</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><em>- tinea versicolor</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>300&nbsp;mg to 400&nbsp;mg once weekly</p></td><td style="vertical-align:top"><p>1 to 3&nbsp;weeks</p></td></tr><tr><td style="vertical-align:top"><p>50&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>2 to 4&nbsp;weeks</p></td></tr><tr><td style="vertical-align:top"><p><em>- tinea unguium</em> (<em>onychomycosis</em>)</p></td><td style="vertical-align:top"><p>150&nbsp;mg once weekly</p></td><td style="vertical-align:top"><p>Treatment should be continued until infected nail is replaced (uninfected nail grows in). Regrowth of fingernails and toenails normally requires 3 to 6&nbsp;months and 6 to 12&nbsp;months, respectively. However, growth rates may vary widely in individuals, and by age. After successful treatment of long-term chronic infections, nails occasionally remain disfigured.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Prophylaxis of candidal infections in patients with prolonged neutropenia</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>200&nbsp;mg to 400&nbsp;mg once daily</p></td><td style="vertical-align:top"><p>Treatment should start several days before the anticipated onset of neutropenia and continue for 7&nbsp;days after recovery from neutropenia after the neutrophil count rises above 1000&nbsp;cells per mm<sup>3</sup>.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Special populations</u></em></p><p><u>&nbsp;</u></p><p><em>Elderly </em></p><p>Dosage should be adjusted based on the renal function (see &ldquo;<em>Renal impairment</em>&rdquo;).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Diflucan is predominantly excreted in the urine as unchanged active substance. No adjustments in single dose therapy are necessary. In patients (including paediatric population) with impaired renal function who will receive multiple doses of fluconazole, an initial dose of 50&nbsp;mg to 400&nbsp;mg should be given, based on the recommended daily dose for the indication. After this initial loading dose, the daily dose (according to indication) should be based on the following table:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Percent of recommended dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;50</p></td><td style="vertical-align:top"><p>100%</p></td></tr><tr><td style="vertical-align:top"><p>&le;50 (no haemodialysis)</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>100% after each haemodialysis</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients on haemodialysis should receive 100% of the recommended dose after each haemodialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Limited data are available in patients with hepatic impairment, therefore fluconazole should be administered with caution to patients with liver dysfunction (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>A maximum dose of 400&nbsp;mg daily should not be exceeded in paediatric population.</p><p>&nbsp;</p><p>As with similar infections in adults, the duration of treatment is based on the clinical and mycological response. Diflucan is administered as a single daily dose.</p><p>&nbsp;</p><p>For paediatric patients with impaired renal function, see dosing in &ldquo;<em>Renal impairment</em>&rdquo;. The pharmacokinetics of fluconazole has not been studied in paediatric population with renal insufficiency (for &ldquo;Term newborn infants&rdquo; who often exhibit primarily renal immaturity please see below).</p><p>&nbsp;</p><p><em>Infants, toddlers and children (from 28&nbsp;days to 11&nbsp;years old):</em></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Indication</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Posology</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Recommendations</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>- Mucosal candidiasis</p></td><td style="vertical-align:top"><p>Initial dose: 6&nbsp;mg/kg</p><p>Subsequent dose: 3&nbsp;mg/kg once daily</p></td><td style="vertical-align:top"><p>Initial dose may be used on the first day to achieve steady state levels more rapidly</p></td></tr><tr><td style="vertical-align:top"><p>- Invasive candidiasis</p><p>- Cryptococcal meningitis</p></td><td style="vertical-align:top"><p>Dose: 6 to 12&nbsp;mg/kg once daily</p></td><td style="vertical-align:top"><p>Depending on the severity of the disease</p></td></tr><tr><td style="vertical-align:top"><p>- Maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of recurrence</p></td><td style="vertical-align:top"><p>Dose: 6 mg/kg once daily</p></td><td style="vertical-align:top"><p>Depending on the severity of the disease</p></td></tr><tr><td style="vertical-align:top"><p>- Prophylaxis of <em>Candida</em> in immunocompromised patients</p></td><td style="vertical-align:top"><p>Dose: 3 to 12&nbsp;mg/kg once daily</p></td><td style="vertical-align:top"><p>Depending on the extent and duration of the induced neutropenia (see Adults posology)</p></td></tr></tbody></table><p>* The capsule formulation is not adapted for use in infants and small children.</p><p><u>&nbsp;</u></p><p><em>Adolescents (from 12 to 17&nbsp;years old):</em></p><p>Depending on the weight and pubertal development, the prescriber would need to assess which posology (adults or children) is the most appropriate. Clinical data indicate that children have a higher fluconazole clearance than observed for adults. A dose of 100, 200 and 400&nbsp;mg in adults corresponds to a 3, 6&nbsp;and 12&nbsp;mg/kg dose in children to obtain a comparable systemic exposure.</p><p>&nbsp;</p><p>Safety and efficacy for genital candidiasis indication in paediatric population has not been established. Current available safety data for other paediatric indications are described in section 4.8. If treatment for genital candidiasis is imperative in adolescents (from 12 to 17 years old), the posology should be the same as adults posology.</p><p><u>&nbsp;</u></p><p><em>Term newborn infants (0 to 27&nbsp;days):</em></p><p>Neonates excrete fluconazole slowly. There are few pharmacokinetic data to support this posology in term newborn infants (see section 5.2).</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Age group</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Posology</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Recommendations</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Term newborn infants (0 to 14&nbsp;days)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>The same mg/kg dose as for infants, toddlers and children should be given every 72&nbsp;hours</p></td><td style="vertical-align:top"><p>A maximum dose of 12&nbsp;mg/kg every 72&nbsp;hours should not be exceeded</p></td></tr><tr><td style="vertical-align:top"><p>Term newborn infants (from 15 to 27&nbsp;days)</p></td><td style="vertical-align:top"><p>The same mg/kg dose as for infants, toddlers and children should be given every 48&nbsp;hours</p></td><td style="vertical-align:top"><p>A maximum dose of 12&nbsp;mg/kg every 48&nbsp;hours should not be exceeded</p></td></tr></tbody></table><p>* The capsule formulation is not adapted for use in infants and small children.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Diflucan may be administered either orally (Capsules, Powder for Oral Suspension and Syrup) or by intravenous infusion (Solution for Infusion), the route being dependent on the clinical state of the patient. On transferring from the intravenous to the oral route, or <em>vice versa</em>, there is no need to change the daily dose.</p><p>&nbsp;</p><p>The physician should prescribe the most appropriate pharmaceutical form and strength according to age, weight and dose. The capsule formulation is not adapted for use in infants and small children. Oral liquid formulations of fluconazole are available that are more suitable in this population.</p><p>&nbsp;</p><p>The capsules should be swallowed whole and independent of food intake.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to related azole substances, or to any of the excipients listed in section 6.1.

Coadministration of terfenadine is contraindicated in patients receiving Diflucan at multiple doses of 400 mg per day or higher based upon results of a multiple dose interaction study. Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine, and erythromycin are contraindicated in patients receiving fluconazole (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Tinea capitis</u></em></p><p>Fluconazole has been studied for treatment of <em>tinea capitis</em> in children. It was shown not to be superior to griseofulvin and the overall success rate was less than 20%. Therefore, Diflucan should not be used for <em>tinea capitis.</em></p><p>&nbsp;</p><p><u>Cryptococcosis</u></p><p>The evidence for efficacy of fluconazole in the treatment of cryptococcosis of other sites (e.g. pulmonary and cutaneous cryptococcosis) is limited, which prevents dosing recommendations.</p><p>&nbsp;</p><p><u>Deep endemic mycoses</u></p><p>The evidence for efficacy of fluconazole in the treatment of other forms of endemic mycoses such as <em>paracoccidioidomycosis, lymphocutaneous sporotrichosis</em> and <em>histoplasmosis</em> is limited, which prevents specific dosing recommendations.</p><p><u>&nbsp;</u></p><p><u>Renal system</u></p><p>Diflucan should be administered with caution to patients with renal dysfunction (see section 4.2).</p><p>&nbsp;</p><p><u>Adrenal insufficiency</u></p><p>Ketoconazole is known to cause adrenal insufficiency, and this could also although rarely seen be applicable to fluconazole. Adrenal insufficiency relating to concomitant treatment with prednisone, see section 4.5 <strong>&lsquo;The effect of fluconazole on other medicinal products&rsquo;</strong>.</p><p><u>&nbsp;</u></p><p><u>Hepatobiliary system</u></p><p>Diflucan should be administered with caution to patients with liver dysfunction.</p><p>&nbsp;</p><p>Diflucan has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions. In cases of fluconazole associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of patient has been observed. Fluconazole hepatotoxicity has usually been reversible on discontinuation of therapy.</p><p>&nbsp;</p><p>Patients who develop abnormal liver function tests during fluconazole therapy must be monitored closely for the development of more serious hepatic injury.</p><p>The patient should be informed of suggestive symptoms of serious hepatic effect (important asthenia, anorexia, persistent nausea, vomiting and jaundice). Treatment of fluconazole should be immediately discontinued and the patient should consult a physician.</p><p>&nbsp;</p><p><u>Cardiovascular system </u></p><p>Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (I<sub>kr</sub>). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4. During post‑marketing surveillance, there have been very rare cases of QT prolongation and <em>torsades&nbsp;de pointes</em> in patients taking Diflucan. These reports included seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant treatment that may have been contributory. Patients with hypokalemia and advanced cardiac failure are at an increased risk for the occurrence of life threatening ventricular arrhythmias and <em>torsades&nbsp;de&nbsp;pointes</em>.</p><p>&nbsp;</p><p>Diflucan should be administered with caution to patients with potentially proarrhythmic conditions.</p><p>&nbsp;</p><p>Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 are contraindicated (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Halofantrine </u></p><p>Halofantrine has been shown to prolong QTc interval at the recommended therapeutic dose and is a substrate of CYP3A4. The concomitant use of fluconazole and halofantrine is therefore not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Dermatological reactions</u></p><p>Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. AIDS patients are more prone to the development of severe cutaneous reactions to many medicinal products. If a rash, which is considered attributable to fluconazole, develops in a patient treated for a superficial fungal infection, further therapy with this medicinal product should be discontinued. If patients with invasive/systemic fungal infections develop rashes, they should be monitored closely and fluconazole discontinued if bullous lesions or erythema multiforme develop.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>In rare cases anaphylaxis has been reported (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Cytochrome P450</u></p><p>Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor. Fluconazole is also a strong inhibitor of CYP2C19. Diflucan treated patients who are concomitantly treated with medicinal products with a narrow therapeutic window metabolised through CYP2C9, CYP2C19 and CYP3A4, should be monitored (see section 4.5).</p><p>&nbsp;</p><p><u>Terfenadine</u></p><p>The coadministration of fluconazole at doses lower than 400&nbsp;mg per day with terfenadine should be carefully monitored (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Candidiasis</u></p><p>Studies have shown an increasing prevalence of infections with <em>Candida</em> species other than <em>C.</em><em>&nbsp;</em><em>albicans</em>. These are often inherently resistant (e.g. <em>C. krusei</em> and <em>C. auris</em>) or show reduced susceptibility to fluconazole (<em>C. glabrata</em>). Such infections may require alternative antifungal therapy secondary to treatment failure. Therefore, prescribers are advised to take into account the prevalence of resistance in various <em>Candida</em> species to fluconazole.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Capsules contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>Diflucan capsules contain less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Concomitant use of the following other medicinal products is contraindicated:</u></em></p><p><u>&nbsp;</u></p><p><u>Cisapride</u>: There have been reports of cardiac events including <em>torsades de pointes</em> in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole 200&nbsp;mg once daily and cisapride 20&nbsp;mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. Concomitant treatment with fluconazole and cisapride is contraindicated (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Terfenadine:</u> Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200&nbsp;mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400&nbsp;mg and 800&nbsp;mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400&nbsp;mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400&nbsp;mg or greater with terfenadine is contraindicated (see section 4.3). The coadministration of fluconazole at doses lower than 400&nbsp;mg per day with terfenadine should be carefully monitored.</p><p><u>&nbsp;</u></p><p><u>Astemizole</u>: Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of <em>torsades de pointes</em>. Coadministration of fluconazole and astemizole is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Pimozide</u>: Although not studied <em>in vitro</em> or <em>in vivo</em>, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of <em>torsades de pointes</em>. Coadministration of fluconazole and pimozide is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Quinidine:</u> Although not studied <em>in vitro</em> or <em>in vivo</em>, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of <em>torsades de pointes</em>. Coadministration of fluconazole and quinidine is contraindicated (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Erythromycin:</u><strong> </strong>Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, <em>torsades de pointes</em>) and consequently sudden heart death. Coadministration of fluconazole and erythromycin is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><em><u>Concomitant use of the following other medicinal products cannot be recommended:</u></em></p><p>&nbsp;</p><p><u>Halofantrine</u>: Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4. Concomitant use of fluconazole and halofantrine has the potential to increase the risk of cardiotoxicity (prolonged QT interval, <em>torsades de pointes</em>) and consequently sudden heart death. This combination should be avoided (see section 4.4).</p><p>&nbsp;</p><p><em><u>Concomitant use that should be used with caution:</u></em></p><p><em><u>&nbsp;</u></em></p><p><u>Amiodarone:</u> Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high dose fluconazole (800 mg).</p><p><u>&nbsp;</u></p><p><em><u>Concomitant use of the following other medicinal products lead to precautions and dose adjustments:</u></em></p><p><em>&nbsp;</em></p><p><u>The effect of other medicinal products on fluconazole</u></p><p>&nbsp;</p><p><u>Rifampicin</u>: Concomitant administration of fluconazole and rifampicin resulted in a 25% decrease in the AUC and a 20% shorter half‑life of fluconazole. In patients receiving concomitant rifampicin, an increase of the fluconazole dose should be considered.</p><p>&nbsp;</p><p>Interaction studies have shown that when oral fluconazole is coadministered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically significant impairment of fluconazole absorption occurs.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide:</u> In a pharmacokinetic interaction study, coadministration of multiple‑dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentration of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics.</p><p>&nbsp;</p><p><u>The effect of fluconazole on other medicinal products</u></p><p><u>&nbsp;</u></p><p>Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4. Fluconazole is also a strong inhibitor of the isozyme CYP2C19. In addition to the observed/documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolised by CYP2C9, CYP2C19 and CYP3A4 coadministered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4‑5&nbsp;days after discontinuation of fluconazole treatment due to the long half‑life of fluconazole (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Abrocitinib</u>: Fluconazole (inhibitor of CYP2C19, 2C9, 3A4) increased exposure of abrocitinib active moiety by 155%. If co-administered with fluconazole, adjust the dose of abrocitinib as instructed in the abrocitinib prescribing information.</p><p><u>&nbsp;</u></p><p><u>Alfentanil</u>:<strong> </strong>During concomitant treatment with fluconazole (400 mg) and intravenous alfentanil (20&nbsp;mg/kg) in healthy volunteers the alfentanil AUC <sub>10 </sub>increased 2-fold, probably through inhibition of CYP3A4.Dose adjustment of alfentanil may be necessary.</p><p><u>&nbsp;</u></p><p><u>Amitriptyline, nortriptyline</u>: Fluconazole increases the effect of amitriptyline and nortriptyline. 5‑nortriptyline and/or S‑amitriptyline may be measured at initiation of the combination therapy and after one week. Dose of amitriptyline/nortriptyline should be adjusted, if necessary</p><p><u>&nbsp;</u></p><p><u>Amphotericin B</u>: Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with <em>C. albicans</em>, no interaction in intracranial infection with <em>Cryptococcus neoformans</em>, and antagonism of the two medicinal products in systemic infection with <em>Aspergillus fumigatus</em>. The clinical significance of results obtained in these studies is unknown.</p><p><u>&nbsp;</u></p><p><u>Anticoagulants</u>: In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. During concomitant treatment with fluconazole and warfarin the prothrombin time was prolonged up to 2‑fold, probably due to an inhibition of the warfarin metabolism through CYP2C9. In patients receiving coumarin‑type or indanedione<em> </em>anticoagulants concurrently with fluconazole the prothrombin time should be carefully monitored. Dose adjustment of the anticoagulant may be necessary.</p><p><u>&nbsp;</u></p><p><u>Benzodiazepines (short acting), i.e. midazolam, triazolam</u>: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. Concomitant intake of fluconazole 200&nbsp;mg and midazolam 7.5&nbsp;mg orally increased the midazolam AUC and half-life 3.7‑fold and 2.2-fold, respectively. Fluconazole 200&nbsp;mg daily given concurrently with triazolam 0.25&nbsp;mg orally increased the triazolam AUC and half-life 4.4‑fold and 2.3-fold, respectively. Potentiated and prolonged effects of triazolam have been observed at concomitant treatment with fluconazole. If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dose, and the patients should be appropriately monitored.</p><p>&nbsp;</p><p><u>Carbamazepine</u>: Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dose adjustment of carbamazepine may be necessary depending on concentration measurements/effect.</p><p><strong>&nbsp;</strong></p><p><u>Calcium channel blockers</u>: Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil and felodipine) are metabolised by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended.</p><p>&nbsp;</p><p><u>Celecoxib</u>: During concomitant treatment with fluconazole (200&nbsp;mg daily) and celecoxib (200&nbsp;mg) the celecoxib C<sub>max</sub> and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole.</p><p><strong>&nbsp;</strong></p><p><u>Cyclophosphamide</u>: Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine.</p><p><u>&nbsp;</u></p><p><u>Fentanyl</u>: One fatal case of fentanyl intoxication due to possible fentanyl fluconazole interaction was reported. Furthermore, it was shown in healthy volunteers that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to respiratory depression. Patients should be monitored closely for the potential risk of respiratory depression. Dosage adjustment of fentanyl may be necessary.</p><p>&nbsp;</p><p><u>HMG-CoA reductase inhibitors</u>: The risk of myopathy and rhabdomyolysis increases (dose‑dependent) when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolised through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin). If concomitant therapy is necessary, the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected. Lower doses of HMG‑CoA reductase inhibitors may be necessary as instructed in the statins prescribing information.</p><p>&nbsp;</p><p><u>Ibrutinib</u>: Moderate inhibitors of CYP3A4 such as fluconazole increase plasma ibrutinib concentrations and may increase risk of toxicity. If the combination cannot be avoided, reduce the dose of ibrutinib to 280 mg once daily (two capsules) for the duration of the inhibitor use and provide close clinical monitoring.</p><p><u>&nbsp;</u></p><p><u>Ivacaftor </u><u>(alone or combined with drugs in the same therapeutic class)</u>: Coadministration with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, increased ivacaftor exposure by 3-fold and hydroxymethyl-ivacaftor (M1) exposure by 1.9-fold. A reduction of the ivacaftor (alone or combined) dose is necessary as instructed in the ivacaftor (alone or combined) prescribing information.</p><p>&nbsp;</p><p><u>Olaparib</u>:<em> </em>Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. If the combination cannot be avoided, limit the dose of olaparib to 200 mg twice daily.</p><p><u>&nbsp;</u></p><p><u>Immunosuppressors (i.e. ciclosporin, everolimus, sirolimus and tacrolimus):</u></p><p><u>&nbsp;</u></p><p><u>Ciclosporin</u>: Fluconazole significantly increases the concentration and AUC of ciclosporin. During concomitant treatment with fluconazole 200 mg daily and ciclosporin (2.7 mg/kg/day) there was a 1.8‑fold increase in ciclosporin AUC. This combination may be used by reducing the dose of ciclosporin depending on ciclosporin concentration.</p><p>&nbsp;</p><p><u>Everolimus:</u> Although not studied <em>in vivo</em> or <em>in vitro</em>, fluconazole may increase serum concentrations of everolimus through inhibition of CYP3A4.</p><p>&nbsp;</p><p><u>Sirolimus</u>:<strong> </strong>Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P‑glycoprotein. This combination may be used with a dose adjustment of sirolimus depending on the effect/concentration measurements.</p><p>&nbsp;</p><p><u>Tacrolimus</u>: Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5&nbsp;times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with nephrotoxicity. Dose of orally administered tacrolimus should be decreased depending on tacrolimus concentration.</p><p><u>&nbsp;</u></p><p><u>Losartan</u>:<strong> </strong>Fluconazole inhibits the metabolism of losartan to its active metabolite (E‑31&nbsp;74) which is responsible for most of the angiotensin II‑receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously.</p><p>&nbsp;</p><p><u>Lurasidone</u>: Moderate inhibitors of CYP3A4 such as fluconazole may increase lurasidone plasma concentrations. If concomitant use cannot be avoided, reduce the dose of lurasidone as instructed in the lurasidone prescribing information.</p><p>&nbsp;</p><p><u>Methadone</u>: Fluconazole may enhance the serum concentration of methadone. Dose adjustment of methadone may be necessary.</p><p>&nbsp;</p><p><u>Non-steroidal anti-inflammatory drugs</u>: The C<sub>max</sub> and AUC of flurbiprofen was increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. Similarly, the C<sub>max</sub> and AUC of the pharmacologically active isomer [S‑(+)‑ibuprofen] was increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400&nbsp;mg) compared to administration of racemic ibuprofen alone.</p><p>&nbsp;</p><p>Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other NSAIDs that are metabolised by CYP2C9 (e.g. naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dose of NSAIDs may be needed.</p><p>&nbsp;</p><p><u>Phenytoin</u>: Fluconazole inhibits the hepatic metabolism of phenytoin. Concomitant repeated administration of 200 mg fluconazole and 250 mg phenytoin intravenously, caused an increase of the phenytoin AUC24 by 75% and C<sub>min</sub> by 128%. With coadministration, serum phenytoin concentration levels should be monitored in order to avoid phenytoin toxicity.</p><p>&nbsp;</p><p><u>Prednisone</u>: There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a three month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued.</p><p>&nbsp;</p><p>Rifabutin: Fluconazole increases serum concentrations of rifabutin, leading to increase in the AUC of rifabutin up to 80%. There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. In combination therapy, symptoms of rifabutin toxicity should be taken into consideration.</p><p>&nbsp;</p><p><u>Saquinavir:</u> Fluconazole increases the AUC and C<sub>max</sub> of saquinavir with approximately 50% and 55% respectively, due to inhibition of saquinavir&rsquo;s hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Interaction with saquinavir/ritonavir has not been studied and might be more marked. Dose adjustment of saquinavir may be necessary.</p><p><u>&nbsp;</u></p><p><u>Sulfonylureas</u>: Fluconazole has been shown to prolong the serum half‑life of concomitantly administered oral sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy volunteers. Frequent monitoring of blood glucose and appropriate reduction of sulfonylurea dose is recommended during coadministration.</p><p>&nbsp;</p><p><u>Theophylline</u>: In a placebo controlled interaction study, the administration of fluconazole 200&nbsp;mg for 14&nbsp;days resulted in an 18% decrease in the mean plasma clearance rate of theophylline. Patients who are receiving high dose theophylline or who are otherwise at increased risk for theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole. Therapy should be modified if signs of toxicity develop.</p><p>&nbsp;</p><p><u>Tofacitinib</u>: Exposure of tofacitinib is increased when tofacitinib is co-administered with medications that result in both moderate inhibition of CYP3A4 and strong inhibition of CYP2C19 (e.g., fluconazole).<sup> </sup>Therefore, it is recommended to reduce tofacitinib dose to 5 mg once daily when it is combined with these drugs.</p><p>&nbsp;</p><p><u>Tolvaptan</u>:&nbsp;Exposure to tolvaptan is significantly increased (200% in AUC; 80% in C<sub>max</sub>) when tolvaptan, a CYP3A4 substrate, is co-administered with fluconazole, a moderate CYP3A4 inhibitor, with risk of significant increase in adverse reactions particularly significant diuresis, dehydration and acute renal failure. In case of concomitant use, the tolvaptan dose should be reduced as instructed in the tolvaptan prescribing information and the patient should be frequently monitored for any adverse reactions associated with tolvaptan.</p><p>&nbsp;</p><p><u>Vinca alkaloids</u>: Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g. vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4.</p><p><u>&nbsp;</u></p><p><u>Vitamin A</u>: Based on a case-report in one patient receiving combination therapy with all‑trans‑retinoid acid (an acid form of vitamin A) and fluconazole, CNS related undesirable effects have developed in the form of pseudotumour <em>cerebri</em>, which disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind.</p><p>&nbsp;</p><p><u>Voriconazole:</u> (CYP2C9, CYP2C19 and CYP3A4 inhibitor): Coadministration of oral voriconazole (400&nbsp;mg Q12h for 1 day, then 200&nbsp;mg Q12h for 2.5 days) and oral fluconazole (400&nbsp;mg on day 1, then 200&nbsp;mg Q24h for 4 days) to 8 healthy male subjects resulted in an increase in C<sub>max</sub> and AUC<sub>&tau;</sub> of voriconazole by an average of 57% (90%&nbsp;CI: 20%, 107%) and 79% (90%&nbsp;CI: 40%, 128%), respectively. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole.</p><p>&nbsp;</p><p><u>Zidovudine:</u> Fluconazole increases C<sub>max</sub> and AUC of zidovudine by 84% and 74%, respectively, due to an approx. 45% decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dose reduction of zidovudine may be considered.</p><p><u>&nbsp;</u></p><p><u>Azithromycin</u>: An open‑label, randomized, three‑way crossover study in 18&nbsp;healthy subjects assessed the effect of a single 1200&nbsp;mg oral dose of azithromycin on the pharmacokinetics of a single 800&nbsp;mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant pharmacokinetic interaction between fluconazole and azithromycin.</p><p>&nbsp;</p><p><u>Oral contraceptives</u>: Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on hormone level in the 50&nbsp;mg fluconazole study, while at 200&nbsp;mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Before initiating treatment, the patient should be informed of the potential risk to the fetus.</p><p>After single dose treatment, a washout period of 1 week (corresponding to 5-6 half-lives) is recommended before becoming pregnant (see section 5.2).</p><p>For longer courses of treatment, contraception may be considered, as appropriate, in women of childbearing potential throughout the treatment period and for 1 week after the final dose.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>Observational studies suggest an increased risk of spontaneous abortion in women treated with fluconazole during the first and/or second trimester compared to women not treated with fluconazole or treated with topical azoles during the same period.</p><p>&nbsp;</p><p>Data from several thousand pregnant women treated with a cumulative dose of &le; 150 mg of fluconazole, administered in the first trimester, show no increase in the overall risk of malformations in the foetus. In one large observational cohort study, first trimester exposure to oral fluconazole was associated with a small increased risk of musculoskeletal malformations, corresponding to approximately 1 additional case per 1000 women treated with cumulative doses &le; 450 mg compared with women treated with topical azoles and to approximately 4 additional cases per 1000 women treated with cumulative doses over 450 mg. The adjusted relative risk was 1.29 (95% CI 1.05 to 1.58) for 150 mg oral fluconazole and 1.98 (95% CI 1.23 to 3.17) for doses over 450 mg fluconazole.</p><p>&nbsp;</p><p>Available epidemiological studies on cardiac malformations with use of fluconazole during pregnancy provide inconsistent results. However, a meta-analysis of 5 observational studies including several thousand pregnant women exposed to fluconazole during the first trimester finds a 1.8-2 fold increased risk of cardiac malformations when compared to no fluconazole use and/or topical azoles use.</p><p>&nbsp;</p><p>Case reports describe a pattern of birth defects among infants whose mothers received high-dose (400 to 800 mg/day) fluconazole during pregnancy for 3 months or more, in the treatment of coccidioidomycosis. The birth defects seen in these infants include brachycephaly, ears dysplasia, giant anterior fontanelles, femoral bowing and radio-humeral synostosis. A causal relationship between fluconazole use and these birth defects is uncertain.</p><p>&nbsp;</p><p>Fluconazole in standard doses and short-term treatments should not be used in pregnancy unless clearly necessary.</p><p>&nbsp;</p><p>Fluconazole in high dose and/or in prolonged regimens should not be used during pregnancy except for potentially life‑threatening infections.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>Fluconazole passes into breast milk to reach concentrations similar to those in plasma (see section 5.2). Breast-feeding may be maintained after a single dose of 150&nbsp;mg fluconazole. Breast-feeding is not recommended after repeated use or after high dose fluconazole. The developmental and health benefits of breast-feeding should be considered along with the mother&rsquo;s clinical need for Diflucan and any potential adverse effects on the breast-fed child from Diflucan or from the underlying maternal condition.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Fluconazole did not affect the fertility of male or female rats (see section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the effects of Diflucan on the ability to drive or use machines.</p><p>Patients should be warned about the potential for dizziness or seizures (see section 4.8) while taking Diflucan and should be advised not to drive or operate machines if any of these symptoms occur.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in association with fluconazole treatment (see section 4.4).</p><p>&nbsp;</p><p>The most frequently (&ge;1/100 to &lt;1/10) reported adverse reactions are headache, abdominal pain, diarrhoea, nausea, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased and rash.</p><p>&nbsp;</p><p>The following adverse reactions have been observed and reported during treatment with Diflucan with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Agranulocytosis, leukopenia, thrombocytopenia, neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hypercholesterolaemia, hypertriglyceridaemia, hypokalemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence, insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Seizures, paraesthesia, dizziness, taste perversion</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Torsade de pointes (see section 4.4), QT prolongation (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Abdominal pain, vomiting, diarrhoea, nausea</p></td><td style="vertical-align:top"><p>Constipation dyspepsia, flatulence, dry mouth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased (see section 4.4), aspartate aminotransferase increased (see section 4.4), blood alkaline phosphatase increased (see section 4.4)</p></td><td style="vertical-align:top"><p>Cholestasis (see section 4.4), jaundice (see section 4.4), bilirubin increased (see section 4.4)</p></td><td style="vertical-align:top"><p>Hepatic failure (see section 4.4), hepatocellular necrosis (see section 4.4), hepatitis (see section 4.4), hepatocellular damage (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash (see section 4.4)</p></td><td style="vertical-align:top"><p>Drug eruption* (see section 4.4), urticaria (see section 4.4), pruritus, increased sweating</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, (see section 4.4), Stevens-Johnson syndrome (see section 4.4), acute generalised exanthematous-pustulosis (see section 4.4), dermatitis exfoliative, angioedema, face oedema, alopecia</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and<u> </u>connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue, malaise, asthenia, fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* including Fixed Drug Eruption</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The pattern and incidence of adverse reactions and laboratory abnormalities recorded during paediatric clinical trials, excluding the genital candidiasis indication, are comparable to those seen in adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>&nbsp;</p><p>This<strong> </strong>To report any side effect(s):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>-&nbsp;&nbsp; Call center: 19999</p><p>-&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of overdose with Diflucan. Hallucination and paranoid behaviour have been concomitantly reported.</p><p>&nbsp;</p><p>In the event of overdose, symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.</p><p>&nbsp;</p><p>Fluconazole is largely excreted in the urine; forced volume diuresis would probably increase the elimination rate. A three‑hour haemodialysis session decreases plasma levels by approximately 50%.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P‑450-mediated 14-alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14-alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P‑450 enzymes than for various mammalian cytochrome P‑450 enzyme systems.</p><p>&nbsp;</p><p>Fluconazole 50&nbsp;mg daily given up to 28&nbsp;days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400&nbsp;mg&nbsp;daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50&nbsp;mg do not affect its metabolism.</p><p>&nbsp;</p><p><u>Susceptibility <em>in vitro</em></u></p><p><em>In vitro</em>, fluconazole displays antifungal activity against clinically common <em>Candida </em>species (including <em>C. albicans, C. parapsilosis, C. tropicalis</em>)<em>.</em> <em>C. glabrata </em>shows<em> </em>reduced susceptibility to fluconazole while <em>C. krusei</em> and <em>C. auris</em> are resistant to fluconazole. The MICs and epidemiological cut-off value (ECOFF) of fluconazole for <em>C. guilliermondii</em> are higher than for <em>C.&nbsp;albicans</em>.</p><p>&nbsp;</p><p>Fluconazole also exhibits activity <em>in vitro</em> against <em>Cryptococcus neoformans</em> and <em>Cryptococcus. gattii </em>as well as the endemic moulds <em>Blastomyces dermatiditis</em>, <em>Coccidioides immitis</em>, <em>Histoplasma capsulatum</em> and <em>Paracoccidioides brasiliensis</em>.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamics relationship</u></p><p>In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to <em>Candida</em> spp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral candidosis and to a lesser extent candidaemia to treatment. Similarly cure is less likely for infections caused by strains with a higher fluconazole MIC.</p><p>&nbsp;</p><p><u>Mechanisms of resistance</u></p><p><em>Candida</em> spp have developed a number of resistance mechanisms to azole antifungal agents. Fungal strains which have developed one or more of these resistance mechanisms are known to exhibit high minimum inhibitory concentrations (MICs) to fluconazole which impacts adversely efficacy <em>in vivo</em> and clinically.</p><p>&nbsp;</p><p>In usually susceptible species of <em>Candida</em>, the most commonly encountered mechanism of resistance development involves the target enzymes of the azoles, which are responsible for the biosynthesis of ergosterol. Resistance may be caused by mutation, increased production of an enzyme, drug efflux mechanisms, or the development of compensatory pathways.</p><p>&nbsp;</p><p>There have been reports of superinfection with <em>Candida</em> species other than <em>C. albicans</em>, which often have inherently reduced susceptibility (<em>C. glabrata</em>) or resistance to fluconazole (e.g. <em>C.&nbsp;krusei</em>, <em>C.&nbsp;auris</em>). Such infections may require alternative antifungal therapy. The resistance mechanisms have not been completely elucidated in some intrinsically resistant (<em>C. krusei</em>) or emerging (<em>C.&nbsp;auris</em>) species of <em>Candida.</em></p><p>&nbsp;</p><p><u>EUCAST Breakpoints</u></p><p>Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility <em>in vitro</em> and clinical response EUCAST‑AFST (European Committee on Antimicrobial Susceptibility Testing‑Subcommittee on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for <em>Candida</em> species (EUCAST Fluconazole rationale document (2020)‑version 3; European Committee on Antimicrobial Susceptibility Testing, Antifungal Agents, Breakpoint tables for interpretation of MICs, Version 10.0, valid from 2020-02-04). These have been divided into non‑species related breakpoints, which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection. These breakpoints are given in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:634px"><tbody><tr><td style="vertical-align:top"><p>Antifungal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p>Species-related breakpoints (S<u>&lt;</u>/R&gt;) in mg/L</p></td><td style="vertical-align:top"><p>Non-species related breakpoints<sup>A</sup><br />S<u>&lt;</u>/R&gt; in mg/L</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Candida<br />albicans</em></p></td><td style="vertical-align:top"><p><em>Candida<br />dubliniensis</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Candida<br />glabrata</em></p></td><td style="vertical-align:top"><p><em>Candida<br />krusei</em></p></td><td style="vertical-align:top"><p><em>Candida<br />parapsilosis</em></p></td><td style="vertical-align:top"><p><em>Candida<br />tropicalis</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p></td><td colspan="2"><p>2/4</p></td><td><p>2/4</p></td><td><p>0.001*/16</p></td><td><p>--</p></td><td><p>2/4</p></td><td><p>2/4</p></td><td style="vertical-align:top"><p>2/4</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>S = Susceptible, R = Resistant</p><p>A = Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.</p><p>&nbsp;<em>-- </em>= Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.<br />&nbsp;* = The entire <em>C. glabrata</em> is in the I category. MICs against <em>C. glabrata</em> should be interpreted as resistant when above 16 mg/L. Susceptible category (&le;0.001 mg/L) is simply to avoid misclassification of &quot;I&quot; strains as &quot;S&quot; strains. I - Susceptible, increased exposure: A microorganism is categorised as Susceptible, increased exposure when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P‑450-mediated 14-alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14-alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P‑450 enzymes than for various mammalian cytochrome P‑450 enzyme systems.</p><p>&nbsp;</p><p>Fluconazole 50&nbsp;mg daily given up to 28&nbsp;days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400&nbsp;mg&nbsp;daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50&nbsp;mg do not affect its metabolism.</p><p>&nbsp;</p><p><u>Susceptibility <em>in vitro</em></u></p><p><em>In vitro</em>, fluconazole displays antifungal activity against clinically common <em>Candida </em>species (including <em>C. albicans, C. parapsilosis, C. tropicalis</em>)<em>.</em> <em>C. glabrata </em>shows<em> </em>reduced susceptibility to fluconazole while <em>C. krusei</em> and <em>C. auris</em> are resistant to fluconazole. The MICs and epidemiological cut-off value (ECOFF) of fluconazole for <em>C. guilliermondii</em> are higher than for <em>C.&nbsp;albicans</em>.</p><p>&nbsp;</p><p>Fluconazole also exhibits activity <em>in vitro</em> against <em>Cryptococcus neoformans</em> and <em>Cryptococcus. gattii </em>as well as the endemic moulds <em>Blastomyces dermatiditis</em>, <em>Coccidioides immitis</em>, <em>Histoplasma capsulatum</em> and <em>Paracoccidioides brasiliensis</em>.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamics relationship</u></p><p>In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to <em>Candida</em> spp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral candidosis and to a lesser extent candidaemia to treatment. Similarly cure is less likely for infections caused by strains with a higher fluconazole MIC.</p><p>&nbsp;</p><p><u>Mechanisms of resistance</u></p><p><em>Candida</em> spp have developed a number of resistance mechanisms to azole antifungal agents. Fungal strains which have developed one or more of these resistance mechanisms are known to exhibit high minimum inhibitory concentrations (MICs) to fluconazole which impacts adversely efficacy <em>in vivo</em> and clinically.</p><p>&nbsp;</p><p>In usually susceptible species of <em>Candida</em>, the most commonly encountered mechanism of resistance development involves the target enzymes of the azoles, which are responsible for the biosynthesis of ergosterol. Resistance may be caused by mutation, increased production of an enzyme, drug efflux mechanisms, or the development of compensatory pathways.</p><p>&nbsp;</p><p>There have been reports of superinfection with <em>Candida</em> species other than <em>C. albicans</em>, which often have inherently reduced susceptibility (<em>C. glabrata</em>) or resistance to fluconazole (e.g. <em>C.&nbsp;krusei</em>, <em>C.&nbsp;auris</em>). Such infections may require alternative antifungal therapy. The resistance mechanisms have not been completely elucidated in some intrinsically resistant (<em>C. krusei</em>) or emerging (<em>C.&nbsp;auris</em>) species of <em>Candida.</em></p><p>&nbsp;</p><p><u>EUCAST Breakpoints</u></p><p>Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility <em>in vitro</em> and clinical response EUCAST‑AFST (European Committee on Antimicrobial Susceptibility Testing‑Subcommittee on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for <em>Candida</em> species (EUCAST Fluconazole rationale document (2020)‑version 3; European Committee on Antimicrobial Susceptibility Testing, Antifungal Agents, Breakpoint tables for interpretation of MICs, Version 10.0, valid from 2020-02-04). These have been divided into non‑species related breakpoints, which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection. These breakpoints are given in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:634px"><tbody><tr><td style="vertical-align:top"><p>Antifungal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p>Species-related breakpoints (S<u>&lt;</u>/R&gt;) in mg/L</p></td><td style="vertical-align:top"><p>Non-species related breakpoints<sup>A</sup><br />S<u>&lt;</u>/R&gt; in mg/L</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Candida<br />albicans</em></p></td><td style="vertical-align:top"><p><em>Candida<br />dubliniensis</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Candida<br />glabrata</em></p></td><td style="vertical-align:top"><p><em>Candida<br />krusei</em></p></td><td style="vertical-align:top"><p><em>Candida<br />parapsilosis</em></p></td><td style="vertical-align:top"><p><em>Candida<br />tropicalis</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p></td><td colspan="2"><p>2/4</p></td><td><p>2/4</p></td><td><p>0.001*/16</p></td><td><p>--</p></td><td><p>2/4</p></td><td><p>2/4</p></td><td style="vertical-align:top"><p>2/4</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>S = Susceptible, R = Resistant</p><p>A = Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.</p><p>&nbsp;<em>-- </em>= Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.<br />&nbsp;* = The entire <em>C. glabrata</em> is in the I category. MICs against <em>C. glabrata</em> should be interpreted as resistant when above 16 mg/L. Susceptible category (&le;0.001 mg/L) is simply to avoid misclassification of &quot;I&quot; strains as &quot;S&quot; strains. I - Susceptible, increased exposure: A microorganism is categorised as Susceptible, increased exposure when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P‑450-mediated 14-alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14-alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P‑450 enzymes than for various mammalian cytochrome P‑450 enzyme systems.</p><p>&nbsp;</p><p>Fluconazole 50&nbsp;mg daily given up to 28&nbsp;days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400&nbsp;mg&nbsp;daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50&nbsp;mg do not affect its metabolism.</p><p>&nbsp;</p><p><u>Susceptibility <em>in vitro</em></u></p><p><em>In vitro</em>, fluconazole displays antifungal activity against clinically common <em>Candida </em>species (including <em>C. albicans, C. parapsilosis, C. tropicalis</em>)<em>.</em> <em>C. glabrata </em>shows<em> </em>reduced susceptibility to fluconazole while <em>C. krusei</em> and <em>C. auris</em> are resistant to fluconazole. The MICs and epidemiological cut-off value (ECOFF) of fluconazole for <em>C. guilliermondii</em> are higher than for <em>C.&nbsp;albicans</em>.</p><p>&nbsp;</p><p>Fluconazole also exhibits activity <em>in vitro</em> against <em>Cryptococcus neoformans</em> and <em>Cryptococcus. gattii </em>as well as the endemic moulds <em>Blastomyces dermatiditis</em>, <em>Coccidioides immitis</em>, <em>Histoplasma capsulatum</em> and <em>Paracoccidioides brasiliensis</em>.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamics relationship</u></p><p>In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to <em>Candida</em> spp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral candidosis and to a lesser extent candidaemia to treatment. Similarly cure is less likely for infections caused by strains with a higher fluconazole MIC.</p><p>&nbsp;</p><p><u>Mechanisms of resistance</u></p><p><em>Candida</em> spp have developed a number of resistance mechanisms to azole antifungal agents. Fungal strains which have developed one or more of these resistance mechanisms are known to exhibit high minimum inhibitory concentrations (MICs) to fluconazole which impacts adversely efficacy <em>in vivo</em> and clinically.</p><p>&nbsp;</p><p>In usually susceptible species of <em>Candida</em>, the most commonly encountered mechanism of resistance development involves the target enzymes of the azoles, which are responsible for the biosynthesis of ergosterol. Resistance may be caused by mutation, increased production of an enzyme, drug efflux mechanisms, or the development of compensatory pathways.</p><p>&nbsp;</p><p>There have been reports of superinfection with <em>Candida</em> species other than <em>C. albicans</em>, which often have inherently reduced susceptibility (<em>C. glabrata</em>) or resistance to fluconazole (e.g. <em>C.&nbsp;krusei</em>, <em>C.&nbsp;auris</em>). Such infections may require alternative antifungal therapy. The resistance mechanisms have not been completely elucidated in some intrinsically resistant (<em>C. krusei</em>) or emerging (<em>C.&nbsp;auris</em>) species of <em>Candida.</em></p><p>&nbsp;</p><p><u>EUCAST Breakpoints</u></p><p>Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility <em>in vitro</em> and clinical response EUCAST‑AFST (European Committee on Antimicrobial Susceptibility Testing‑Subcommittee on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for <em>Candida</em> species (EUCAST Fluconazole rationale document (2020)‑version 3; European Committee on Antimicrobial Susceptibility Testing, Antifungal Agents, Breakpoint tables for interpretation of MICs, Version 10.0, valid from 2020-02-04). These have been divided into non‑species related breakpoints, which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection. These breakpoints are given in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:634px"><tbody><tr><td style="vertical-align:top"><p>Antifungal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p>Species-related breakpoints (S<u>&lt;</u>/R&gt;) in mg/L</p></td><td style="vertical-align:top"><p>Non-species related breakpoints<sup>A</sup><br />S<u>&lt;</u>/R&gt; in mg/L</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><em>Candida<br />albicans</em></p></td><td style="vertical-align:top"><p><em>Candida<br />dubliniensis</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><em>Candida<br />glabrata</em></p></td><td style="vertical-align:top"><p><em>Candida<br />krusei</em></p></td><td style="vertical-align:top"><p><em>Candida<br />parapsilosis</em></p></td><td style="vertical-align:top"><p><em>Candida<br />tropicalis</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p></td><td colspan="2"><p>2/4</p></td><td><p>2/4</p></td><td><p>0.001*/16</p></td><td><p>--</p></td><td><p>2/4</p></td><td><p>2/4</p></td><td style="vertical-align:top"><p>2/4</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>S = Susceptible, R = Resistant</p><p>A = Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints.</p><p>&nbsp;<em>-- </em>= Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product.<br />&nbsp;* = The entire <em>C. glabrata</em> is in the I category. MICs against <em>C. glabrata</em> should be interpreted as resistant when above 16 mg/L. Susceptible category (&le;0.001 mg/L) is simply to avoid misclassification of &quot;I&quot; strains as &quot;S&quot; strains. I - Susceptible, increased exposure: A microorganism is categorised as Susceptible, increased exposure when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content:</u></p><p>Lactose monohydrateMaize starchColloidal anhydrous silicaMagnesium stearateSodium lauryl sulfate</p><p>&nbsp;</p><p><u>Capsule shell composition:</u></p><p>50&nbsp;mg&nbsp;capsules</p><p>Gelatin</p><p>Titanium dioxide&nbsp;</p><p>Patent blue&nbsp;V&nbsp;</p><p>&nbsp;</p><p>150&nbsp;mg capsules</p><p>Gelatin</p><p>Titanium dioxide&nbsp;</p><p>Patent blue&nbsp;V&nbsp;</p><p>&nbsp;</p><p>200&nbsp;mg capsules</p><p>Gelatin</p><p>Titanium dioxide&nbsp;</p><p>Erythrosin&nbsp;</p><p>Indigo carmine&nbsp;</p><p>&nbsp;</p><p><u>Printing ink:</u></p><p>Shellac (glaze), black iron oxide, N‑Butyl alcohol, dehydrated alcohol, purified water, propylene glycol, industrial methylated spirit, isopropyl alcohol, strong ammonia solution, potassium hydroxide</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 60 months

Do not use Diflucan Capsules after the expiry date which is stated on the carton/blister after EXP:. The expiry date refers to the last day of that month.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>Store below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear PVC blister packs or white opaque PVC/PVDC blister packs with aluminium foil backing.</p><p>&nbsp;</p><p>150 mg: Each pack contains 1 capsule.</p><p>50 mg and 200&nbsp;mg: Each pack contains 7 capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
PFIZER HOLDING FRANCE
23-25, AVENUE DU DOCTEUR LANNELONGUE
75014 PARIS, FRANCE

Manufacturer 
FAREVA AMBOISE 
ZONE INDUSTRIELLE
29 ROUTE DES INDUSTRIES
37530 POCE-SUR-CISSE, FRANCE

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	March 2024


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>